Residency · Residency · Medicine Pediatrics

Systemic Lupus Erythematosus: Pediatric Onset vs. Adult Onset

Overview

SLE is a chronic, multisystem autoimmune disease characterized by autoantibody production and immune complex deposition. ~15-20% of SLE cases are diagnosed before age 18 (childhood-onset SLE, cSLE) cSLE is more aggressive than adult-onset SLE: higher rates of nephritis, CNS involvement, hematologic abnormalities, and damage accrual. Female predominance in both populations (adult 9:1; pediatric 4-5:1 before puberty, increases post-puberty) Racial disparities are striking: higher incidence and severity in Black, Hispanic, and Asian populations.

Diagnosis

Classification Criteria

2019 EULAR/ACR Classification Criteria: entry criterion of ANA >= 1:80, then additive scoring across clinical and immunologic domains; score >= 10 classifies as SLE. Clinical domains: constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal. Immunologic domains: antiphospholipid antibodies, complement (low C3/C4), SLE-specific antibodies (anti-dsDNA, anti-Smith) Same criteria apply to children and adults. Sensitivity ~96%, specificity ~93%.

Key Autoantibodies

ANA: sensitive (~95%) but not specific; nearly universal in SLE. Anti-dsDNA: specific for SLE (~95%); levels correlate with disease activity, especially nephritis. Anti-Smith (anti-Sm): highly specific for SLE (~99%) but less sensitive (~30%) Anti-Ro/SSA and anti-La/SSB: associated with neonatal lupus, photosensitivity, subacute cutaneous lupus. Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein): thrombosis and pregnancy complications. Anti-ribosomal P: associated with neuropsychiatric lupus and hepatitis in cSLE.

Complement

Low C3 and C4 levels indicate active disease (consumption by immune complexes) CH50 screens for total complement function. Homozygous complement deficiency (C1q, C2, C4) predisposes to early-onset SLE.

<image>Diagnostic approach to SLE showing EULAR/ACR 2019 classification criteria with weighted scoring across clinical and immunologic domains and key autoantibody profiles</image>

Clinical Manifestations: Pediatric vs. Adult

Mucocutaneous

Malar (butterfly) rash: spares nasolabial folds; present in ~60-80% of cSLE vs ~50% of adults. Discoid lupus: more common in adults; can cause permanent scarring and alopecia. Photosensitivity: common in both; requires rigorous sun protection. Oral/nasal ulcers: often painless; can be missed on exam. Non-scarring alopecia: diffuse or patchy; common during flares. Raynaud phenomenon: vasospasm of digits; more common in adults.

Renal (Lupus Nephritis)

cSLE: 50-80% develop nephritis (vs 30-50% in adults) Earlier onset and more severe in cSLE; ISN/RPS Classification:; Class I: minimal mesangial; Class II: mesangial proliferative; Class III: focal proliferative (< 50% glomeruli); Class IV: diffuse proliferative (>= 50% glomeruli) — most common and most severe. Class V: membranous; Class VI: advanced sclerotic; Presentation: proteinuria, hematuria, hypertension, edema, rising creatinine; Urine sediment: RBC casts, dysmorphic RBCs; Renal biopsy is essential for classification and treatment guidance; 10-year renal survival has improved to >90% with modern therapy.

Neuropsychiatric (NPSLE)

19 recognized NPSLE syndromes (ACR classification) More common in cSLE (20-40%) than adult SLE. Most common: cognitive dysfunction, headache, mood disorder, seizures, cerebrovascular disease. Serious manifestations: psychosis, transverse myelitis, cerebral vasculitis. Diagnosis is challenging: exclude infection, metabolic causes, medication effects. MRI, CSF analysis, neuropsychological testing as indicated. Anti-ribosomal P and antiphospholipid antibodies associated with NPSLE.

Hematologic

Cytopenias are common and often the presenting feature in cSLE. Autoimmune hemolytic anemia (AIHA): Coombs-positive; more common in cSLE. Leukopenia/lymphopenia: lymphopenia <1000 is a classification criterion. Thrombocytopenia: can be severe; may be the presenting feature. Antiphospholipid syndrome: thrombosis risk in both populations.

Musculoskeletal

Non-erosive polyarthritis is the most common manifestation of SLE across all ages. Jaccoud arthropathy: reducible deformities from ligament laxity (not erosive) Avascular necrosis (osteonecrosis): especially hip and knee; related to corticosteroid use.

Cardiovascular

Pericarditis (most common cardiac manifestation); Libman-Sacks endocarditis (verrucous vegetations, usually on mitral valve); Accelerated atherosclerosis: major cause of late mortality in adult SLE; Myocarditis: rare but life-threatening.

Treatment

General Principles

Hydroxychloroquine (HCQ): CORNERSTONE of SLE management at ALL ages. Reduces flares, damage accrual, thrombosis, and mortality. Continue during pregnancy (safe; reduces neonatal lupus risk) Dose: 5 mg/kg/day (max 400 mg/day) to minimize retinal toxicity risk. Annual ophthalmologic screening (OCT) after 5 years of use (or earlier if risk factors) Retinal toxicity risk: cumulative dose-dependent; irreversible if not detected early.

Mild Disease (Skin, Joints, Serositis)

HCQ + NSAIDs; Low-dose prednisone for flares (target lowest effective dose); Topical steroids and calcineurin inhibitors for skin disease; Methotrexate or azathioprine for steroid-sparing.

Moderate Disease

HCQ + moderate-dose corticosteroids (0.5 mg/kg/day) + steroid-sparing DMARD. Mycophenolate mofetil (MMF): increasingly first-line for maintenance. Azathioprine: safe in pregnancy; alternative maintenance agent. Belimumab (anti-BLyS/BAFF): approved as add-on therapy for adults and children >= 5 years; reduces flares and steroid use.

Severe Disease (Nephritis Class III-V, CNS, Severe Cytopenias)

Induction therapy: Pulse IV methylprednisolone (1g x 3 days) followed by oral prednisone taper. MMF (preferred induction for many patients, especially Black and Hispanic patients per ALMS trial) OR. IV cyclophosphamide (Euro-Lupus protocol: 500 mg every 2 weeks x 6 doses; or NIH protocol: higher doses monthly x 6) Maintenance therapy: MMF or azathioprine. Continue HCQ. Taper steroids to lowest dose (goal: prednisone <= 5 mg/day or off) Voclosporin: calcineurin inhibitor approved for lupus nephritis in adults; added to MMF background; AURORA trial showed superior renal response. Anifrolumab: anti-type I interferon receptor; approved for moderate-severe adult SLE; not yet in pediatric indications but studied.

Refractory Disease

Rituximab (anti-CD20): used off-label for refractory nephritis, refractory cytopenias, NPSLE; RCTs were negative but real-world evidence supports benefit. Cyclophosphamide for severe refractory disease. Plasma exchange for catastrophic antiphospholipid syndrome or TTP-like presentations. HSCT: investigational for severe refractory SLE. CAR-T cell therapy: emerging reports of durable remission in refractory SLE (KYV-101 and others)

<image>Treatment algorithm for lupus nephritis showing biopsy-guided classification-based management from induction through maintenance therapy with key differences in pediatric versus adult regimens</image>

Monitoring and Disease Activity Assessment

Disease Activity Scores

SLEDAI-2K: most widely used; composite score of 24 weighted items. BILAG: organ-specific; useful for clinical trials. Physician Global Assessment (PGA): VAS scale.

Routine Monitoring

CBC, CMP, ESR, CRP at every visit; Anti-dsDNA and complement levels (C3, C4) — correlate with activity; Urinalysis with microscopy at every visit (detect nephritis flares early); Spot urine protein/creatinine ratio; Lipid panel (cardiovascular risk), blood glucose (steroid effects); Bone density monitoring with chronic steroid use.

Growth and Development in cSLE

Linear growth: impaired by active disease and corticosteroid use. Delayed puberty: may occur with active disease or cyclophosphamide. Monitor growth velocity, bone age, Tanner staging. Minimize steroid exposure; use steroid-sparing agents aggressively.

Pregnancy and Reproductive Health

Pregnancy in SLE is high-risk: increased preeclampsia, preterm birth, flares. Pre-pregnancy: disease should be quiescent for >= 6 months; switch to pregnancy-safe medications. Safe in pregnancy: HCQ (continue!), azathioprine, low-dose prednisone, calcineurin inhibitors. Contraindicated: MMF (teratogenic — neural tube defects), methotrexate, cyclophosphamide, belimumab (insufficient data) Anti-Ro/SSA positive women: risk of neonatal lupus (rash, congenital heart block); serial fetal echocardiograms from 16-26 weeks; HCQ reduces risk. Antiphospholipid syndrome in pregnancy: aspirin + LMWH prophylaxis. Fertility preservation: discuss before cyclophosphamide (gonadotoxic); GnRH agonist co-treatment may be protective.

Clinical Pearls

Any child with unexplained cytopenias, nephritis, rash, or arthritis should have ANA checked — cSLE is often the unifying diagnosis. Hydroxychloroquine should essentially NEVER be discontinued in SLE — it reduces mortality, flares, damage, and thrombosis; compliance should be verified (serum HCQ levels available) cSLE patients with nephritis need renal biopsy — class guides treatment; do not treat empirically. Fatigue is the most common and most debilitating symptom reported by SLE patients — it is often undertreated and multifactorial (disease activity, depression, sleep disruption, deconditioning) Steroid use is the strongest modifiable predictor of damage accrual in SLE — strive for prednisone <= 5 mg/day (or off) in all patients. Adolescents with cSLE need proactive reproductive health counseling: effective contraception (avoid estrogen-containing OCPs if antiphospholipid antibodies positive), pregnancy planning, teratogenic medication management. CAR-T cell therapy represents a potential paradigm shift in refractory SLE — early data show deep, drug-free remission in selected patients.

References

• Aringer M, Costenbader K, Daikh D, et al. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
• Harry O, Yasin S, Gideon B. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr. 2018;196:22-30.
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis. Ann Rheum Dis. 2020;79(6):713-723.
• Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and Safety of Voclosporin versus Placebo for Lupus Nephritis (AURORA 1). Lancet. 2021;397(10289):2070-2080.

Read this lecture as Markdown